Elidel Sales To Rebound In Early 2006 Despite Cancer Risk Concerns – Novartis
This article was originally published in The Pink Sheet Daily
Executive Summary
Elidel sales should rebound in early 2006 from their recent decline resulting from concerns over the eczema treatment's potential cancer risk, Novartis Pharmaceuticals CEO Paolo Costa said March 15
You may also be interested in...
Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk
Novartis expects labeling negotiations will begin within the next few weeks and says a "black box" is unjustified. A medication guide will also be required for the eczema treatments, FDA says.
"Black Box" For Protopic, Elidel Is "Blunt" But Necessary Instrument, Advisory Cmte. Says
Although noting that data suggesting a cancer risk from the topical eczema treatments is not definitive, the panel concludes that a black box warning is the best approach to discourage off-label use. A medication guide should also be mandated, the committee says.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter